Molecular Partners (MOLN) Stock Price, News & Analysis

Company Overview

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Key Stats

• Today's Range: $4.20 to $4.56
• 50-Day Range: $3.76 to $5.46
• 52-Week Range: $3.32 to $12.70
• Volume: 4,064 shs
• Average Volume: 19,732 shs
• Market Capitalization: $172.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Strong Buy

Molecular Partners Stock Analysis - MarketRank™

Molecular Partners scored higher than 43% of companies evaluated by MarketBeat, and ranked 635th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Molecular Partners has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Molecular Partners has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Molecular Partners are expected to decrease in the coming year, from ($1.93) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Molecular Partners is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Molecular Partners is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Molecular Partners has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of Molecular Partners has been sold short.

Short Interest Ratio / Days to Cover

Molecular Partners has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Molecular Partners has recently decreased by 6.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Molecular Partners does not currently pay a dividend.

Dividend Growth

Molecular Partners does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the float of Molecular Partners has been sold short.

Short Interest Ratio / Days to Cover

Molecular Partners has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Molecular Partners has recently decreased by 6.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.47

News Sentiment

Molecular Partners has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Molecular Partners this week, compared to 1 article on an average week.

MarketBeat Follows

Only 2 people have added Molecular Partners to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Molecular Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.93% of the stock of Molecular Partners is held by insiders.

Percentage Held by Institutions

Only 26.55% of the stock of Molecular Partners is held by institutions.

MOLN Stock Analysis - Frequently Asked Questions

How have MOLN shares performed this year?

Molecular Partners' stock was trading at $4.75 at the beginning of the year. Since then, MOLN shares have decreased by 10.1% and is now trading at $4.2710.
View the best growth stocks for 2025 here.

How were Molecular Partners' earnings last quarter?

Molecular Partners AG (NASDAQ:MOLN) issued its earnings results on Thursday, March, 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative trailing twelve-month return on equity of 39.31% and a negative net margin of 1,043.01%.

When did Molecular Partners IPO?

Molecular Partners (MOLN) raised $81 million in an IPO on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.

Who are Molecular Partners' major shareholders?

Top institutional investors of Molecular Partners include Suvretta Capital Management LLC (5.50%) and BVF Inc. IL (3.35%).

How do I buy shares of Molecular Partners?

Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Molecular Partners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include PayPal (PYPL), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Robinhood Markets (HOOD), Taiwan Semiconductor Manufacturing (TSM) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 3/29/2025
• Next Earnings (Estimated): 4/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MOLN
• CIK: 1745114
• Web: www.molecularpartners.com
• Phone: 41-44-755-7700
• Fax: N/A
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +181.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-69,040,000.00
• Net Margins: -1,043.01%
• Pretax Margin: -1,043.08%
• Return on Equity: -39.31%
• Return on Assets: -35.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.33
• Quick Ratio: 14.33

Sales & Book Value

• Annual Sales: $4.97 million
• Price / Sales: 34.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.41 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 40,375,000
• Free Float: 37,969,000
• Market Cap: $172.44 million
• Optionable: Not Optionable
• Beta: 1.06